Leber Hereditary Optic Neuropathy — the most common inherited optic neuropathy, where idebenone therapy can preserve or restore vision when initiated early after symptom onset, but only with confirmed molecular diagnosis.
Whole genome sequencing reads the complete mitochondrial genome — identifying the three primary LHON variants (m.11778G>A, m.3460G>A, m.14484T>C) that account for 95% of cases and determine visual prognosis.
Leber Hereditary Optic Neuropathy
Leber hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial optic neuropathy caused by pathogenic variants in the mitochondrial genome (mtDNA). Three primary variants account for approximately 95% of all LHON cases: m.11778G>A (MT-ND4, ~70% of cases), m.3460G>A (MT-ND1, ~13%), and m.14484T>C (MT-ND6, ~14%). These variants impair mitochondrial complex I function, causing selective degeneration of retinal ganglion cells — the neurons whose axons form the optic nerve. LHON affects approximately 1 in 25,000-50,000 and shows marked male predominance (~5:1 male-to-female ratio), suggesting modifying nuclear or hormonal factors.
LHON typically presents in young adults (median onset age 20-30 years) with acute or subacute painless central vision loss, initially unilateral then rapidly progressing to bilateral involvement within weeks to months. Vision deteriorates to legal blindness (visual acuity typically 20/200 to counting fingers) with dense central scotoma. The acute phase shows optic disc pseudoedema and peripapillary telangiectatic microangiopathy on fundoscopy. Spontaneous partial visual recovery occurs in approximately 20-25% of patients with m.11778G>A and up to 50-65% of patients with m.14484T>C — making genotype the strongest predictor of visual prognosis.
Idebenone (Raxone/Catena), a synthetic analog of coenzyme Q10, was approved by the EMA in 2015 for treatment of LHON. Idebenone bypasses the complex I defect, shuttling electrons directly to complex III. Clinical trials demonstrated that idebenone preserves or improves visual acuity when initiated early after symptom onset — before retinal ganglion cell loss becomes irreversible. The treatment window is narrow: benefit is greatest when idebenone is started within the first year of vision loss, particularly in the first affected eye (before the second eye becomes involved). Gene therapy (lenadogene nolparvovec, intravitreal AAV delivery of MT-ND4) is approved in several countries for m.11778G>A LHON.
The m.14484T>C variant has the best spontaneous recovery rate (~50-65%) while m.11778G>A has the worst (~20-25%). Genotype is the strongest predictor of visual prognosis — directly affecting treatment urgency and counseling.
LHON is mitochondrial, maternally inherited, and variably penetrant. Whole genome sequencing reads both nuclear and mitochondrial genomes — identifying the LHON variant and assessing heteroplasmy levels that influence penetrance.
Idebenone and gene therapy require rapid molecular diagnosis — the treatment window closes as retinal ganglion cells die
Idebenone produces the best visual outcomes when started within months of symptom onset, before retinal ganglion cell degeneration becomes irreversible. Gene therapy (lenadogene nolparvovec) is specifically approved for m.11778G>A LHON and requires molecular confirmation for prescribing. Any young adult presenting with acute painless bilateral sequential vision loss should have immediate mtDNA evaluation for LHON — delays in molecular diagnosis directly translate to treatment delays that reduce the chance of visual recovery.
Maternal family members carry the same mtDNA variant — presymptomatic identification enables lifestyle modification and early treatment readiness
All maternal relatives of a confirmed LHON patient carry the same mtDNA variant, though penetrance varies widely (approximately 50% of males and 15% of females become symptomatic). Presymptomatic carriers benefit from lifestyle counseling — tobacco smoking and heavy alcohol use are established triggers for LHON conversion. Additionally, presymptomatic carriers can be educated about early symptoms, enabling immediate idebenone initiation at the first sign of vision change rather than after delayed clinical evaluation.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Leber Hereditary Optic Neuropathy and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
